Table 3.

Multivariate analysis of prognostic factors for cancer-specific survival

Variable	Training cohort (n = 10,612)			Validation cohort (n = 4548)
	HR	95% CI	P	HR	95% CI	P
Age(ref = ≧ 60 years old)	0.699	0.654–0.748	< 0.001	0.734	0.662–0.813	< 0.001
Tumor sizea	1.001	1.001–1.002	< 0.001	1.001	1.00–1.002	0.060
LONTa	0.469	0.435–0.505	< 0.001	0.489	0.437–0.547	< 0.001
Sex (ref = male)	0.988	0.927–1.053	0.599	0.989	0.897–1.090	0.820
T stage (ref= T4b)
T1	0.405	0.345–0.476	< 0.001	0.416	0.320–0.540	< 0.001
T2	0.510	0.440–0.591	< 0.001	0.541	0.427–0.687	< 0.001
T3	0.722	0.645–0.809	< 0.001	0.744	0.614–0.902	0.003
T4a	0.855	0.761–0.959	< 0.001	0.891	0.734–1.083	0.247
N stage (ref= N3b)
N0	0.294	0.260–0.332	< 0.001	0.295	0.244–0.356	< 0.001
N1	0.492	0.436–0.555	< 0.001	0.496	0.414–0.595	< 0.001
N2	0.616	0.548–0.691	< 0.001	0.571	0.478–0.681	< 0.001
N3a	0.766	0.684–0.857	< 0.001	0.844	0.710–1.004	0.056
Differentiation (ref = G3 + G4)						0.035
G1	0.744	0.618–0.894	< 0.001	0.856	0.658–1.112	0.245
G2	0.801	0.744–0.863	< 0.001	0.871	0.780–0.971	0.013
Histology (ref = adenocarcinoma)	1.035	0.962–1.113	0.356	1.007	0.903–1.124	0.900
Location (ref = cardiac)
Middleb	0.645	0.593–0.702	< 0.001	0.727	0.641–0.824	< 0.001
Antrum/pylorus	0.697	0.642–0.756		0.674	0.595–0.763	< 0.001
Other	0.737	0.667–0.814	0.043	0.719	0.617–0.838	< 0.001
Race (ref = others)
White	1.257	1.161–1.361	< 0.001	1.182	1.046–1.336	0.007
Black	1.320	1.187–1.468	< 0.001	1.279	1.086–1.507	0.003

CI Confidence interval, HR Hazard ratio, LONT Log odds of negative lymph nodes/T stage, ref: Reference

^aThese variables were treated as continuous data

^bThe location included the body, fundus, greater curvature and lesser curvature of the stomach